Studies suggest novel targeted therapies may benefit patients with metastatic HR+/ HER2- breast cancer

Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The data will be shared in oral presentations today at the 2023 San Antonio Breast Cancer Symposium (SABCS).